Bioprocessing & Bioproduction In-Depth Focus 2021
Posted: 21 December 2021 | European Pharmaceutical Review | No comments yet
In this in-depth focus, experts discuss how a future skills shortage may impact the biopharma industry and the key considerations when validating assays and analytical methods for ATMPs.
- The weakest link – biopharma workforce development
Killian O’Driscoll, Director of Projects at the National Institute for Bioprocessing Research and Training (NIBRT), highlights the plight of a future skills shortage in the global biopharma industry as state-of-the-art therapy production evolves at a rapid pace. - Critical steps when validating an assay or analytical method for cell and gene therapy products
Dr Kiren Baines, Analytics Lead at eXmoor Pharma, details some of the critical steps when validating an assay or analytical method, including key considerations for developing an experimental plan aligned with ICH guidelines.
Issue
Related topics
Analytical techniques, Assays, Biologics, Biopharmaceuticals, Bioproduction, Drug Manufacturing, ICH guidelines, Industry Insight, QA/QC, Recruitment, Therapeutics
